1.2% Rosuvastatin Subgingivally Delivered In Chronic Periodontitis With Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The purpose of the present study was to evaluate the effects of subgingival delivery of 1.2%
Rosuvastatin (RSV) gel as an adjunct to scaling and root planing in chronic periodontitis
(CP) with Type 2 diabetes mellitus patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Government Dental College and Research Institute, Bangalore